CV Therapeutics Sets Sights On Imdur With Ranolazine Development
Executive Summary
CV Therapeutics is looking at Schering-Plough's Imdur (isosorbide) as a market "benchmark" for its Phase III anti-angina agent ranolazine.
You may also be interested in...
Ranexa Target Population Is 10%-25% Of Angina Patients; Sampling Will Be Key
CV Therapeutics' launch of its second-line angina product Ranexa (ranolazine) will include an aggressive sampling program
Ranexa Target Population Is 10%-25% Of Angina Patients; Sampling Will Be Key
CV Therapeutics' launch of its second-line angina product Ranexa (ranolazine) will include an aggressive sampling program
Innovex Sales Support For CVT Angina Drug Based On Percentage Formula
Quintiles' contract sales division Innovex would receive up to one-third of the first two years of sales from a chronic stable angina treatment being developed by CV Therapeutics, under a commercialization deal announced May 11.